Henlius Reports 2026 Interim Results, Global Growth Advances
Shanghai, China,August 20, 2026 Henlius announced its 2026 interim results, highlighting continued financial growth, expanding global commercialization, and progress...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Shanghai, China,August 20, 2026 Henlius announced its 2026 interim results, highlighting continued financial growth, expanding global commercialization, and progress...
Needham, Massachusetts, USA,August 20, 2026 Evolved By Nature, Inc. announced that its programmable peptide platform has been used in...
